Does the media favor AVLN or BIOA?

In the previous week, Avalyn Pharma and Avalyn Pharma both had 4 articles in the media. Avalyn Pharma's average media sentiment score of 0.66 beat BioAge Labs' score of 0.62 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, BIOA or CRON?

Cronos Group has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAge Labs $8.99M 34.04 -$80.61M -$2.38 N/A Cronos Group $146.59M 8.08 -$9.45M $0.20 16.08

Is BIOA or CRON more profitable?

Cronos Group has a net margin of 39.08% compared to BioAge Labs' net margin of -912.26%. Cronos Group's return on equity of 4.85% beat BioAge Labs' return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -912.26% -28.99% -27.09% Cronos Group 39.08% 4.85% 4.62%

Does the media favor BIOA or CRON?

In the previous week, BioAge Labs had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.86 beat BioAge Labs' score of 0.62 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CALT or BIOA?

BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 448.46%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable earnings & valuation, HROW or BIOA?

Harrow has higher revenue and earnings than BioAge Labs. Harrow is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 4.19 -$5.14M -$1.00 N/A BioAge Labs $8.99M 34.04 -$80.61M -$2.38 N/A

Is HROW or BIOA more profitable?

Harrow has a net margin of -13.51% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Harrow's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -13.51% -38.00% -3.37% BioAge Labs -912.26% -28.99% -27.09%

Does the media prefer HROW or BIOA?

In the previous week, Harrow had 3 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Harrow and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.62 beat Harrow's score of 0.44 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioAge Labs (BIOA) Competitors

$6.61 -0.20 (-2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$6.70 +0.09 (+1.29%)

As of 07:30 PM Eastern

Compare

BIOA vs. AVLN, CRON, LBRX, CALT, and HROW

Should you buy BioAge Labs stock or one of its competitors? BioAge Labs's main competitors and comparable companies include Avalyn Pharma (AVLN), Cronos Group (CRON), LB Pharmaceuticals (LBRX), Calliditas Therapeutics AB (publ) (CALT), and Harrow (HROW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BioAge Labs compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Avalyn Pharma has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. Avalyn Pharma's return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
BioAge Labs	-912.26%	-28.99%	-27.09%

In the previous week, Avalyn Pharma and Avalyn Pharma both had 4 articles in the media. Avalyn Pharma's average media sentiment score of 0.66 beat BioAge Labs' score of 0.62 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma presently has a consensus price target of $60.00, indicating a potential upside of 112.01%. BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 448.46%. Given BioAge Labs' higher probable upside, analysts plainly believe BioAge Labs is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Avalyn Pharma has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
BioAge Labs	$8.99M	34.04	-$80.61M	-$2.38	N/A

Summary

Avalyn Pharma beats BioAge Labs on 7 of the 11 factors compared between the two stocks.

How does BioAge Labs compare to Cronos Group?

BioAge Labs (NASDAQ:BIOA) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Cronos Group has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	34.04	-$80.61M	-$2.38	N/A
Cronos Group	$146.59M	8.08	-$9.45M	$0.20	16.08

Cronos Group has a net margin of 39.08% compared to BioAge Labs' net margin of -912.26%. Cronos Group's return on equity of 4.85% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Cronos Group	39.08%	4.85%	4.62%

BioAge Labs currently has a consensus price target of $36.57, indicating a potential upside of 448.46%. Cronos Group has a consensus price target of $2.30, indicating a potential downside of 28.46%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

BioAge Labs has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

In the previous week, BioAge Labs had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.86 beat BioAge Labs' score of 0.62 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.7% of Cronos Group shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cronos Group beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

LB Pharmaceuticals currently has a consensus price target of $51.67, suggesting a potential upside of 40.19%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 448.46%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

LB Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. LB Pharmaceuticals' return on equity of -25.92% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
BioAge Labs	-912.26%	-28.99%	-27.09%

LB Pharmaceuticals has higher earnings, but lower revenue than BioAge Labs. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
BioAge Labs	$8.99M	34.04	-$80.61M	-$2.38	N/A

In the previous week, BioAge Labs had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 4 mentions for BioAge Labs and 0 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.02 beat BioAge Labs' score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
LB Pharmaceuticals	Positive
BioAge Labs	Positive

Summary

LB Pharmaceuticals beats BioAge Labs on 8 of the 13 factors compared between the two stocks.

How does BioAge Labs compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
BioAge Labs	-912.26%	-28.99%	-27.09%

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BioAge Labs had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for BioAge Labs and 0 mentions for Calliditas Therapeutics AB (publ). BioAge Labs' average media sentiment score of 0.62 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
BioAge Labs	Positive

BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 448.46%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Calliditas Therapeutics AB (publ) has higher revenue and earnings than BioAge Labs. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
BioAge Labs	$8.99M	34.04	-$80.61M	-$2.38	N/A

Summary

BioAge Labs beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Harrow?

Harrow (NASDAQ:HROW) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Harrow has a net margin of -13.51% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
BioAge Labs	-912.26%	-28.99%	-27.09%

In the previous week, Harrow had 3 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Harrow and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.62 beat Harrow's score of 0.44 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow presently has a consensus target price of $66.17, indicating a potential upside of 117.35%. BioAge Labs has a consensus target price of $36.57, indicating a potential upside of 448.46%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts plainly believe BioAge Labs is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Harrow has higher revenue and earnings than BioAge Labs. Harrow is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	4.19	-$5.14M	-$1.00	N/A
BioAge Labs	$8.99M	34.04	-$80.61M	-$2.38	N/A

Harrow has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Harrow and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$312.56M	$12.18B	$7.09B	$13.24B
Dividend Yield	N/A	2.63%	2.53%	15.89%
P/E Ratio	N/A	797.15	274.61	26.05
Price / Sales	33.75	751.64	600.51	90.03
Price / Cash	N/A	81.79	77.38	51.25
Price / Book	0.87	10.47	10.92	6.31
Net Income	-$80.61M	$2.83B	$3.50B	$361.43M
7 Day Performance	-6.24%	-1.65%	-2.11%	-1.67%
1 Month Performance	-32.07%	-5.77%	-6.34%	-3.94%
1 Year Performance	12.03%	-3.80%	8.81%	2.77%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOA BioAge Labs	2.8478 of 5 stars	$6.61 -2.9%	$36.57 +453.3%	+15.0%	$312.56M	$8.99M	N/A	62
AVLN Avalyn Pharma	3.4993 of 5 stars	$28.67 +2.1%	$60.00 +109.3%	N/A	$1.27B	N/A	N/A	55	Analyst Forecast
CRON Cronos Group	1.3606 of 5 stars	$3.43 +2.5%	$2.30 -32.8%	+20.7%	$1.26B	$146.59M	17.13	610
LBRX LB Pharmaceuticals	2.3287 of 5 stars	$37.81 +1.3%	$49.63 +31.3%	+136.5%	$1.22B	N/A	N/A	27	Positive News Analyst Forecast
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. AVLN, CRON, LBRX, CALT, and HROW

How does BioAge Labs compare to Avalyn Pharma?

Summary

How does BioAge Labs compare to Cronos Group?

Summary

How does BioAge Labs compare to LB Pharmaceuticals?

Summary

How does BioAge Labs compare to Calliditas Therapeutics AB (publ)?

Summary

How does BioAge Labs compare to Harrow?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. AVLN, CRON, LBRX, CALT, and HROW

How does BioAge Labs compare to Avalyn Pharma?

Is AVLN or BIOA more profitable?

Does the media favor AVLN or BIOA?

Do analysts recommend AVLN or BIOA?

Which has higher valuation & earnings, AVLN or BIOA?

Summary

How does BioAge Labs compare to Cronos Group?

Which has higher valuation & earnings, BIOA or CRON?

Is BIOA or CRON more profitable?

Do analysts recommend BIOA or CRON?

Which has more volatility and risk, BIOA or CRON?

Does the media favor BIOA or CRON?

Do insiders & institutionals believe in BIOA or CRON?

Summary

How does BioAge Labs compare to LB Pharmaceuticals?

Do analysts recommend LBRX or BIOA?

Is LBRX or BIOA more profitable?

Which has preferable earnings & valuation, LBRX or BIOA?

Does the media refer more to LBRX or BIOA?

Summary

How does BioAge Labs compare to Calliditas Therapeutics AB (publ)?

Which has more risk & volatility, CALT or BIOA?

Is CALT or BIOA more profitable?

Do institutionals and insiders believe in CALT or BIOA?

Does the media refer more to CALT or BIOA?

Do analysts recommend CALT or BIOA?

Which has preferable earnings & valuation, CALT or BIOA?

Summary

How does BioAge Labs compare to Harrow?

Is HROW or BIOA more profitable?

Does the media prefer HROW or BIOA?

Do analysts recommend HROW or BIOA?

Which has preferable earnings & valuation, HROW or BIOA?

Which has more risk and volatility, HROW or BIOA?

Do institutionals & insiders believe in HROW or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools